8:05 am Chair’s Opening Remarks

Enhancing Preclinical Development & Translation Research

8:15 am Biomarkers for Basic and Translational Research


  • Pillars of aging are interactive, so we might expect complexity in any biomarkers of aging
  • Linking biomarkers to physiological declines that could be measured through increased frailty or decreased activities of daily living
  • Exploring the need to accommodate variance in biomarkers and account for “medical conditions that are not age” as potential exclusion criteria for the occurrence of outliers with increasing age

8:45 am Altered Methylation Landscapes in Biological Aging


  • Discussing differences between existing epigenetic measures of aging, e.g. Epigenetic Clocks
  • Presenting novel higher-order epigenetic measures
  • Highlighting the application of such measures for evaluating Geroprotective Interventions

9:15 am Rejuvenation Biotechnology: Addressing Delivery Challenges in Gene & Stem Cell Therapy


  • Analyzing how regenerative medicine and other new biomedical technologies will eventually be so comprehensive that people will stay truly youthful however long they live
  • Outlining an innovative approach for stem cell delivery for neurodegenerative diseases
  • Exploring gene therapy potential in aging and how to deliver large cargos with very high insertion-site specificity

9:45 am Morning Refreshments & Networking

10:15 am Therapies for Thymic Regeneration and Cholesterol Catabolism

  • Reason CEO, Repair Biotechnologies


  • Developing a safe and effective therapy for thymic regeneration and immune system restoration
  • Building on LysoSENS to develop a gene therapy for cholesterol catabolism
  • Presenting the latest data

10:45 am Hard Problems Need Hard Assets: Building, Discovering & Translating A Small Molecule Senolytic


  • Developing first-in-class small molecule senolytic drugs for pathways of aging
  • Analyzing the latest data

11:15 am Panel Discussion: Tackling Preclinical & Translational Challenges in Aging-Related Therapeutics


  • How applicable to human aging is any given result in a model organism?
  • How to promote advances in biomarker discovery and validation in aging
  • Defining routes for translational success from discovery to clinic – what will be the key factors for generating successful results?
  • Standardizing different classes of therapeutic approaches to achieve effective anti-aging outcomes

12:00 pm Lunch & Networking

Exploring Clinical Development, Regulatory & Commercial Considerations

1:00 pm TAMEing Aging

  • Nir Barzilai MD. Director, Institute for Aging Research , Albert Einstein College of Medicine


  • Exploring metformin – a generic, cheap and safe drug used to treat Type 2 diabetes mellitus (T2DM), which targets biology of aging, extends health span and life span in animals
  • Showing that metformin targets this biology in muscle and adipose tissue of elderly
  • Numerous clinical and observational studies in humans show that metformin therapy delays diabetes, cardiovascular diseases, all kind of cancers, Alzheimer’s and mortality
  • Describing a novel study design that addresses the need to define aging in a clinical way
  • Addressing regulation – FDA is helping design this study so if outcomes are achieved aging will become a regulatory target

1:30 pm Innovating R&D for Ageing: A Systematic, Comprehensive & Innovative Approach to The Development of Therapies for Ageing


  • Analyzing the fragmentated clinical translation of pathways that control biological ageing
  • Discussing current business/investment models in R&D and the their short comings as
    applicable to ageing research
  • Developing an innovative drug development engine for ageing – establishing Life
  • Discussing the Life Bioscience’s investment and operating model, the science underlying
    the programs, and how we can translate drugs to treat ageing into the clinic

2:00 pm Mastermind Session: Supporting the Successful Discovery & Development of Innovative Medicines Against Diseases of Aging


This session facilitates in-depth discussions among participants in an informal environment. After splitting into groups, participants will discuss key issues and challenges regarding the current landscape of aging research and related drug development.

2:45 pm Afternoon Refreshments & Networking

3:15 pm TORC1 Inhibition as an Immunotherapy to Decrease Respiratory Tract Infections in the Elderly


  • Discussing the role of mTOR in aging
  • Overviewing resTORbio’s TORC1 inhibitors
  • Reviewing of Phase 2 clinical trials analyzing the effects of TORC1 inhibitors on immune function and respiratory tract infection rates in elderly subjects

3:45 pm Addressing The Challenges of the Aging Population Requires Taking A Holistic View


  • Analyzing the link between general function and clinical outcomes in the elderly
  • What can we learn from rare genetic disorders?
  • How to address variability in target populations?
  • Addressing the need for innovation in clinical trial design in genetic and age-related disorders

4:15 pm Clinical Evaluation & Regulatory Considerations in the Approval of Biopharmaceuticals for Health-Span Indications

  • Brian Huber Chief Operations and Scientific Officer, Carolina Longevity Institute LLC (CLI)


  • Discussing how the clinical development strategy and regulatory approval pathway for health-span and longevity related biopharmaceutical drugs is still evolving and being established
  • Exploring lessons learned from other examples where the clinical indication needed to be established and the approval pathway created
  • Drawing parallels and hypothesizing pathways

4:45 pm Chair’s Closing Remarks